An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.

Jitka FucikovaMichal HenslerLenka KasikovaTereza LanickovaJosef PasulkaJana RakovaJana DrozenovaTessa FredriksenMarek HraskaTereza HrnciarovaKlara SochorovaDaniela RozkovaLudek SojkaPavel DundrJan LacoTomas Brtnicky Ivan Praznovec Michael J Halaska Lukáš Rob Aleš Ryška An Coosemans Ignace VergoteDavid CibulaJirina Bartunkova Jerome GalonLorenzo GalluzziRadek Spisek

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our findings suggest that while patients with highly infiltrated, "hot" EOCs benefit from chemotherapy, women with "cold" EOCs may instead require DC-based vaccination to jumpstart clinically relevant anticancer immune responses.

Keyphrases

dendritic cells
immune response
regulatory t cells
bone marrow
cell therapy
locally advanced
risk factors
chemotherapy induced
rectal cancer